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Background: Little is known of ICD therapy in patients who receive implantable cardioverter-defibrillators (ICD) for genetic heart disease (GHD). 
The aim of this study was to determine if ICD therapy (Rx) differed amongst GHD patients, and between GHD patients and patients who did not have 
GHD, including ischemic and non-ischemic cardiomyopathy.
methods and results: Of 2177 patients who received ICDs at our center from 2000-2011, 316 (14.6%) had GHD, including arrhythmogenic 
right ventricular dysplasia (ARVD), channelopathies (CHAN), hypertrophic cardiomyopathy (HCM), and left ventricular non-compaction (LVNC). Age, 
indication, average follow-up and left ventricular ejection fraction (LVEF), and appropriate ICD Rx are shown in the table. 
ARVD
n=51
CHAN
n=82
HCM
n=144
LVNC
n=39
P
value
Average Age ± SD 43.2±17.4 51.2±19.0 43.8±16.9 50.7±14.8 0.004
Average Follow-up (mos) 54.0±32.7 65.1±38.9 65.9±43.2 38.1±28.7 <0.0001
% Primary prevention 70.6% 39.0% 86.1% 82.1% <0.0001
Average LVEF ± SD 58.4±10.0 57.1±8.6 61.6±12.7 37.7±16.9 <0.0001
ICD Therapy 24% 29% 17% 21% <0.0001
Shock 16% 23% 14% 5% 0.0686
Antitachycardia pacing 24% 21% 8% 18% 0.0164
Time to 1st ICD Therapy (mos) 2.9 10.6 20.5 4.9 0.0213
Compared to 1861 patients without GHD, patients with GHD were younger (46.2±17.7 vs 66.7±12.5; p<0.0001), and less likely to receive ICD Rx 
(21.5% vs 30.0%;p=0.0025) but more received inappropriate shocks (11.7% vs 7.4%; p=0.0041); however, the proportions receiving an ICD for 
primary prevention (69.9% vs 70.6%; p=0.8656), and the median time to 1st ICD Rx (12.2 vs 17.2 mos; p=0.605) were similar.
conclusion: Significant differences exist in the need for ICD therapy and the time to 1st ICD Rx amongst patients who have GHD. However, all GHD 
subgroups benefited from high-voltage shocks and antitachycardia pacing. In general, GHD patients were younger and less likely to receive ICD Rx 
than patients without GHD.
